PAPERS

Published:

1. Caygill CPJ, Reed PI, McIntyre A, Hill MJ (1998). The UK National Barrett’s Oesophagus Registry: A Study Between Two Centres. Eur J. Cancer Prev; 7: 161-164.

2. Caygill CPJ, Reed PI, Johnston BJ, Hill MJ, Ali M, Levi S (1999). A single centre’s 20 years’ experience of columnar-lined (Barrett’s) oesophagus diagnosis. Eur J Gastroent and Hep 11: 1355 - 1358.

3. Caygill CPJ, Reed PI, Hill MJ, Watson A (1999) An initial comparison of nine centres registering patients with the UK National Barrett’s Oesophagus Registry (UKBOR). Eur J. Cancer Prev; 8: 539-542.

4. Caygill CPJ, Johnston DA, Lopez M, Johnston BJ, Watson A, Reed PI, Hill MJ. (2002). Lifestyle Factors and Barrett’s Oesophagus. Amer J Gastroenterology 97: 1328-1331.

5. Caygill CPJ, Watson A, Reed PI, Hill MJ (on behalf of the UK National Barrett’s Oesophagus Registry (UKBOR) and the twenty seven participating centres)* (2003). Characteristics and Regional Variations of Patients with Barrett’s oesophagus in the UK. Eur J Gastro Hep 15: 1217-1222.

6. Van Blankenstein M, Looman CWN, Johnston BJ, Caygill CPJ (2005). Age and sex distribution of the prevalence of Barrett’s Esophagus found in a primary referral endoscopy center. Amer J Gastroenterology 100: 568-576.

7. Ramus JR, Gatenby PAC, Caygill CPJ, Watson A (2007) Helicobacter Pylori infection and severity of reflux-induced oesophageal disease in a cohort of patients with Columnar-Lined Oesophagus Dig Dis Sci 52: 2821-2825 .

8. Gatenby PAC, Caygill CPJ, Ramus J R, Charlett A, Watson A (2007) Short Segment Columnar-Lined Oesophagus (CLO) - an underestimated cancer risk? A large cohort study of the relationship between Barrett's CLO segment length and adenocarcinoma risk. Eur J Gastro Hep 19: 969-975.

9. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2007). Does the length of columnar-lined esophagus change with time? Dis Oesophagus 20: 497-503.

10. Ramus JR, Caygill CPJ, Gatenby PAC, Watson A (2008) Current UK practice in the diagnosis and management of columnar-lined oesophagus; results of the UK National Barrett's Oesophagus Registry (UKBOR) endoscopist questionnaire. Eur J Cancer Prev 17: 422-425.

11. Gatenby PAC, Caygill CPJ, Ramus J R, Charlett A, Watson A (2008). "Barrett's Columnar-Lined Esophagus: Demographic and Lifestyle Associations and Adenocarcinoma Risk" Digestive Diseases and Sciences 53: 1175-85.

12. Gatenby PAC, Ramus JR, Caygill CPJ, Shepherd NA, Watson A (2008).
The Relevance of the Detection of Intestinal Metaplasia in Non-Dysplastic Columnar-Lined Oesophagus. Scand J Gastro 43: 524-530

13. Gatenby PAC, Ramus JR, Caygill CPJ, Charlett A, Winslet MC, Watson A (2009). Treatment modality and risk of development of dysplasia and adenocarcinoma in columnar-lined esophagus. Dis Oesophagus 22: 133-42

14. Ramus JR, Gatenby PAC, Caygill CPJ, Winslet MC, Watson A (2009) Surveillance of Barrett's columnar-lined oesophagus in the UK: endoscopic intervals and frequency of detection of dysplasia. Eur J Gastro Hep 21: 636-641.

15. Wall CM, Charlett A, Caygill CPJ, Gatenby PAC, Ramus JR, Winslet M, Watson A. (2009) Are Newly Diagnosed Columnar-lined Oesophagus(CLO) Patients Getting Younger? Eur J Gastro Hep (in press).

16. Gatenby PAC, Ramus JR, Caygill CPJ, Charlett A, Winslet MC, Watson A (2009). The Influence of Symptom Type and Duration on the Fate of the Metaplastic Columnar-Lined Oesophagus. Aliment Pharmacol Ther 29: 1096-1105.

17. Gatenby PAC, Ramus JR, Caygill CPJ, Shepherd NA, Winslet MC, Watson A (2009). Routinely diagnosed low grade dysplasia in Barrett’s oesphagus: A population-based study of natural history. Histopathology 54:814-9

18. Gatenby PAC, Ramus JR, Caygill CPJ, Winslet MC, Watson A (2009). Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in a multicentre cohort. Eur J Cancer Prev. (in press).

MD THESES

1. Gatenby PAC (2008). The Natural History of Columnar-Lined Oesophagus, University of London.

2. Ramus JR (2008). Barrett's oesophagus and its progression to
adenocarcinoma: A study of patient profile. University of London.

LETTERS

1. Caygill CPJ (1999). Treating upper digestive track cancers as a single entity may be misleading. British Medical Journal (BMJ) 318, 1289-90.

2. Caygill CPJ, Watson A (2006) The association of body mass index with Barrett’s oesphagus. Alimt Pharmacol Ther 23, 1027-1028.

INVITED PAPERS

1. Caygill CPJ, Reed PI, Watson A, Hill MJ. (2000). The UK National Barrett’s Oesophagus Registry (UKBOR): aims and progress. Eur J Cancer Prev. 10: 97-99.

2. Caygill CPJ (2001). Barrett’s Oesophagus and Oesophageal Adenocarcinoma: the Epidemiological Evidence. Acta Endoscopica 31, 485-490.

INVITED REVIEWS

1. Reed PI, Caygill CPJ, Watson A (2003). The United Kingdom Barrett’s Oesophagus Registry (UKBOR) - the first six years. Gastroenterologia Polska 10: 299-304.

2. Caygill CPJ, Watson A, Lao-Sirieix P, (2004). Barrett’s Oesophagus and Adenocarcinoma. World Journal of Surgical Oncology 2: 12. (Web publication) www.wjso.com/content/2/1/12.

REPORTS

1. Caygill CPJ, Zaninotto G, Rugge M (2008) Barrett’s Registries in Europe: Report of an International Workshop. Eur J Cancer Prev.17: 426- 429.

ABSTRACTS AND POSTERS

Published:

1. Caygill CPJ, Reed PI, Hill MJ, Watson A (1997). The UK National Barrett’s Oesophagus Registry. Gut 40 (suppl.1): A35.

2. Caygill CPJ, Reed PI, Johnston, BJ, Hill MJ, Levi S (1997). A Study of Barrett’s Oesophagus Registrations From a Single Centre Over a 20 Year Period. Gut 41 (suppl.3): E43.

3. Caygill CPJ, Reed PI, Watson A, McIntyre A, Hill MJ (1998). The First Year of the UK National Barrett’s Esophagus Registry. Gastroenterology 114, A87

4. Reed PI, Caygill CPJ, Hill MJ, Watson A (1998). The UK National Barrett’s Oesophagus Registry (UKBOR): The first Two Years. Eur. J. Surgical Oncology 24, 457.

5. Caygill CPJ, Reed PI, Hill MJ (1998).UK National Barrett’s Oesophagus Registry: A Comparison of Nine Centres. Digestion 59 (suppl. 3):580.

6. Watson A, Reed PI, Caygill CPJ, Epstein O, Winslett MC, Pounder RE (1999). Changing incidence of columnar-lined (Barrett’s) oesophagus (CLO) in the UK. Gut 44, Suppl. 1, A45

7. Caygill CPJ, Reed PI, Johnston BJ, Hill MJ, Deru K, Watson A, Levi S (1998) UK National Barrett’s Oesophagus Registry: role of obesity, tobacco and alcohol in Barrett’s oesophagus. Eur. J. Cancer Prev. 7, 481

8. Watson A, Reed PI, Caygill CPJ, Epstein O, Winslett MC, Pounder RE (1999). Changing incidence of columnar-lined (Barrett’s) oesophagus (CLO) in the UK. Gastroenterology 116, Suppl 2, A351.

9. Caygill CPJ, Jankowski J, Ali M, Reed PI, Hill MJ (1999). Expression of Bile Acid Receptors: A preliminary report. Eur. J. Cancer Prev.8, 354.

10. Caygill CPJ, Reed PI, Hill MJ, Watson A (1999). The UK National Barrett’s Oesophagus Registry: a Progress Report.. Eur. J. Cancer Prev. 8, 354

11. Caygill CPJ, Reed PI, Johnston DA, Lopez M, Hill MJ (1999) Obesity and Barrett’s oesophagus in a UK Population. 1999. Gut. 45, A81.

12. Caygill C, Reed P, Watson A, Hill M (2000). UK National Barrett’s Oesophagus Registry: An Update. Eur. J Cancer Prev. 9: 456-7.

13. Caygill C, Reed P, Watson A, Hill M (2000). UK National Barrett’s Oesophagus Registry: An Update. Gut 47, (suppl. III) A68.

14. Watson A, Caygill CP (2002). The frequency of development of adenocarcinoma in Barrett’s oesophagus – implications for surveillance. Gastroenterology 122: A350.

15. Van Blankenstein M, Caygill CPJ, Johnston BJ (2002). The prevalence of Barrett’s oesophagus (BO) in an U.K. Centre over 15 years. Gut 50, (suppl. II) A123

16. Gatenby PAC, Caygill CPJ, Charlett A, Watson A (2003) Length of Barrett’s Oesophagus Segment: Demographic Associations and Cancer Risk. Gut 52: (suppl. I) A41.

17. Gatenby PAC, Caygill CPJ, Watson A, Charlett A (2003) Length of Barrett’s Oesophagus Segment: Demographic Associations and Cancer Risk. Gastroenterology 124: A638.

18. Gatenby P, Caygill C, Ramus J, Bateson M, Johnston D, Watson A (2003) Distribution of obesity by age and gender in Barrett’s oesophagus patients at two culturally different centres registering with UK National Barrett’s Oesophagus Registry. J Clin Oncology 38: 185 (P57). (Selected for oral presentation at plenary session)

19. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2003). Association Between Lifestyle Factors and Histology in Barrett's Oesophagus. Gut 52: (suppl Vl) A221.

20. Gatenby PAC, Caygill CPJ, Ramus JR, Watson A (2004). Metaplasia-Dysplasia-Adenocarcinoma Sequence in Barrett's Oesophagus (CLO) in a Large UK Series. Gut 53: (suppl III) A55.

21. Gatenby PAC, Caygill CPJ, Ramus JR, Watson A (2004). Does the Length of the Columnar-lined Oesophagus (CLO) Change with Time. Gut 53: (suppl III) A35. (Selected for plenary session).

22. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2004). Incidence of adenocarcinoma in short and long segment columnar-lined oesophagus. Gastroenterology 126: (suppl 2) A308. (awarded a distinction).

23. Gatenby PAC, Caygill CPJ, Ramus JR, Watson A (2004). Does the length of columnar-lined oesophagus (CLO) change with time. Gastroenterology 126: (suppl 2) A177. (selected as a poster of special interest).

24. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2004). Histological Sequence in a Large UK Series of Columnar-Lined Oesophagus (CLO). Diseases of the Esophagus 17: (suppl 1) A22

25. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2004). Histological Sequence in a Large UK Series of Columnar-Lined Oesophagus (CLO). Diseases of the Esophagus 17: (suppl 1) A126-7

26. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2004). Adenocarcinoma (AC) Risk in Short (SS) and Long (LS) Segment Columnar-Lined Oesophagus (CLO). Diseases of the Esophagus 17: (suppl 1) A46-7

27. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2004). Adenocarcinoma (AC) Risk in Short (SS) and Long (LS) Segment Columnar-Lined Oesophagus (CLO). Diseases of the Esophagus 17: (suppl1) A127.

28. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2004). Change in Length of the Columnar-Lined Oesophagus (CLO) over Time and Cancer Risk. Diseases of the Esophagus 17: (suppl1) A16.

29. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2004). Time course of metaplastic and dysplastic changes in columnar-lined oesophagus (CLO) and relationship to symptom onset. Accepted by UEGW Sep. 2004. Gut 53 (suppl VI) A99.

30. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2004). Relationship of presenting symptoms to outcome in columnar-lined oesophagus (CLO). Gut 53 (suppl VI) A101.

31. Ramus JR, Gatenby PAC, Caygill CPJ, Watson A (2004). Helicobacter pylori infection and severity of oesophageal disease in a cohort of patients with Barrrett's oesophagus. Accepted by UEGW for oral presentation. Gut 53 (suppl VI) A61.

32. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2005). Impact of treatment on Barrett’s Cancer incidence. Gut 54 (suppl 11) A52.

33. Gatenby PAC Caygill CPJ, Ramus JR, Watson A (2005). Barrett’s oesophgus treatment: effect on high grade dysplasia – oesophagageal cancer incidence. Gastoenterology 128, (suppl 2), S1713.

34. Gatenby PAC, Caygill CPJ, Ramus JR, Shepherd N, Watson A (2005). The significance of detection of intestinal metaplasia (IM) in columnar- lined oesophagus (CLO). The Canadian J of Gastroenterology HOME WCOG abstracts R0078.

35. Ramus JR, Gatenby PAC, Caygill CPJ, Watson A (2005). Endoscopic surveillance intervals for columnar-lined oesophagus (CLO) in the U.K. and Impact on detection of dysplastic disease. The Canadian J of Gastroenterology HOME WCOG abstracts R0090.

36. Ramus JR, Caygill CPJ, Gatenby PAC and Watson A. (2006). Diagnosis and management of Barrett’s oesophagus; results of the UK National Barrett’s Oesophagus Registry (UKBOR) endoscopist questionnaire. Gut 55 (suppl 11) A104-105.

37. Wall C, Charlett A, Caygill C, Gatenby P, Ramus J, Watson A (2006). Are newly diagnosed columnar-lined oesophagus patients getting younger? J Clin Gastroenterol 40 (suppl 4) S207.

38. Gatenby P, Ramus J R, Caygill C P J, Watson A (2007). The Relevance of Low-grade Dysplasia in Columnar-lined Oesophagus. Gut 56 (suppl 11) A70.

39. Gatenby P, Ramus J R, Caygill C P J, Watson A (2007). The Outcome of Low-Grade Dysplasia in Barrett's Columnar-Lined Esophagus - A large cohort study from the UK National Barrett's Oesophagus Registry. Gastrointestinal Endoscopy 65: AB133

40. Gatenby PAC; Ramus JR; Caygill CPJ; Winslet MC; Watson A (2008). No Evidence of Aspirin Chemoprotection in Barrett's Adenocarcinoma of the Esophagus? Gastrointestinal Endoscopy 67: AB178 – AB179

41 Caygill, CPJ, Charlett A, Wall C, Bardhan KD, Royston C, Gatenby P, Ramus JR, Winslet M (2009) Blood group distribution in reflux disease, columnar-lined oesophagus and oesophageal adenocarcinoma compared with the blood donating population. Gastroenterology 136: (Supple 1) A601.

42 Ramus JR, Gatenby PAC, Caygill CPJ, Watson A, Winslet M (2009) The risk of smoking on development of dysplastic disease in patients with columnarised oesophagus. (in press).

Notes

1. Reed PI, Watson A (1996). UK National Barrett’s Oesophagus Registry. Gut; 39: 499-500.

2. Reed PI, Watson A (1996). UK National Barrett’s Oesophagus Registry. Eur J Cancer Prev; 5: 207.

3. Salmon P (2007) Barrett’s Oesophagus Foundation. Gastrointestinal Nursing; 5: 14-17.

back to top